Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lee S. Schwartzberg, MD
Acorn Cardiovascular, Inc.
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Advanced Medical Specialties
Miami, Florida, United States
- Northeast Georgia Cancer Care
Athens, Georgia, United States
- Augusta Oncology Associates
Augusta, Georgia, United States
- Medical & Surgical Specialists
Galesburg, Illinois, United States
- Oncology Specialists
Park Ridge, Illinois, United States
- Hematology Oncology Centers of the Northern Rockies
Billings, Montana, United States
- Las Vegas Cancer Center
Henderson, Nevada, United States
- the Lancaster Cancer Center, Ltd
Lancaster, Pennsylvania, United States
- the West Clinic
Memphis, Tennessee, United States
- Cancer Specialists of Tidewater
Chesapeake, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2007
- Primary completion
- 30 Sept 2011
- Completion
- 30 Sept 2011
- Last update posted
- 1 Feb 2013
- Registered enrollment
- 41
- Registry id
- NCT00534417
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.